GKIM
ARQT icon

GW&K Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

GW&K Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8M Buy
1,288,018
+299,631
+30% +$6.98M 0.26% 141
2026
Q1 		$23.3M Sell
988,387
-20,193
-2% -$515K 0.21% 178
2025
Q4 		$29.3M Sell
1,008,580
-163,461
-14% -$4.18M 0.25% 158
2025
Q3 		$22.1M Sell
1,172,041
-206,391
-15% -$3.25M 0.2% 187
2025
Q2 		$19.3M Sell
1,378,432
-133,779
-9% -$1.88M 0.17% 205
2025
Q1 		$23.7M Sell
1,512,211
-31,873
-2% -$449K 0.22% 178
2024
Q4 		$21.5M Sell
1,544,084
-49,546
-3% -$543K 0.18% 197
2024
Q3 		$14.8M Sell
1,593,630
-74,349
-4% -$734K 0.13% 234
2024
Q2 		$15.5M Sell
1,667,979
-53,274
-3% -$482K 0.14% 220
2024
Q1 		$17.1M Buy
1,721,253
+80,928
+5% +$604K 0.15% 206
2023
Q4 		$5.3M Sell
1,640,325
-428,968
-21% -$1.17M 0.05% 264
2023
Q3 		$11M Buy
2,069,293
+6,610
+0.3% +$56.2K 0.11% 234
2023
Q2 		$19.7M Buy
2,062,683
+157,961
+8% +$1.75M 0.19% 187
2023
Q1 		$21M Buy
1,904,722
+352,708
+23% +$5.1M 0.2% 175
2022
Q4 		$23M Buy
1,552,014
+643,101
+71% +$11.2M 0.23% 162
2022
Q3 		$17.4M Buy
908,913
+232,235
+34% +$5.26M 0.19% 180
2022
Q2 		$14.4M Buy
676,678
+464,178
+218% +$9.52M 0.16% 191
2022
Q1 		$4.09M Buy
+212,500
New +$3.59M 0.04% 271

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GW&K Investment Management's ARQT Position: Q2 2026 in Review

GW&K Investment Management increased its Arcutis Biotherapeutics (ARQT) stake by 30% in Q2 2026, buying an estimated $6.98M and bringing the position to 1,288,018 shares worth $33.8M. The position accounts for 0.26% of the portfolio, ranked #141.

GW&K Investment Management first reported a position in ARQT in Q1 2022 and has held it in 18 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • GW&K Investment Management held 1,288,018 shares of Arcutis Biotherapeutics worth $33.8M as of Q2 2026.
  • GW&K Investment Management bought 299,631 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.98M.
  • Arcutis Biotherapeutics made up 0.26% of GW&K Investment Management's portfolio in Q2 2026, its #141 holding.
  • GW&K Investment Management first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 18 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.